Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients

Millward, Michael; Boyer, Michael; Lehnert, Manfred; Clarke, Stephen; Rischin, Danny; Goh, Boon Cher; Wong, John; McNeil, Edward; Bishop, James F.

doi:10.1093/annonc/mdg118

Cited by 93 publications

(76 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The probability of developing neutropenia varies for each individual regimen; currently, predictions are based on the treatment regimen used and the experience of the attending physician (Sato et al, 2012 anticancer drugs (Lyman and Delgado, 2003;Millward et al, 2003;Timmer-Bonte et al, 2005). By contrast, few investigations have examined the predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with CRPC.…”

Section: Predictive Factors For Neutropenia After Docetaxel-based Sysmentioning

confidence: 99%

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Kwon¹,

Oh²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The aim of this study was to determine predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with castration-resistant prostate cancer (CRPC). The study included 40 Korean CRPC patients who were treated with several cycles of docetaxel plus prednisolone from May 2005 to May 2012. Patients were evaluated for neutropenia risk factors and for the incidence of neutropenia. In this study, nine out of forty patients (22.5%) developed neutropenia during the first cycle of docetaxel-based systemic chemotherapy. Four experienced grade 2, three grade 3, and one grade 4 neutropenia. Multivariate analysis showed that pretreatment white blood cell (WBC) count (p=0.042), pretreatment neutrophil count (p=0.015), pretreatment serum creatinine level (p=0.027), and pretreatment serum albumin level (p=0.017) were significant predictive factors for neutropenia. In conclusion, pretreatment WBC counts, neutrophil counts, serum creatinine levels, and serum albumin levels proved to be significant independent risk factors for the development of neutropenia induced by docetaxel-based systemic chemotherapy in patients with CRPC.

show abstract

Section: Predictive Factors For Neutropenia After Docetaxel-based Sysmentioning

confidence: 99%

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Kwon¹,

Oh²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…We were interested in the activity of the combination of docetaxel and carboplatin as second-line treatment in NSCLC patients, who were treated with platinum or non-platinum-containing regimens as first-line therapy. In chemotherapy-naive patients the combination of docetaxel and carboplatin was active with response rates between 27 and 44%, and acceptable toxicity [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC

Wachters¹,

Putten

Boezen

et al. 2004

Lung Cancer

View full text Add to dashboard Cite

“…overall treatment efficacy was favorable, but was not enhanced by COX-2 inhibitors in terms of tumor response (36.0%), OS (13.7 months) and 1-year survival ratio (56.0%). Previous phase II-III trials of docetaxel and carboplatin without COX-2 inhibitors for advanced NSCLC demonstrated that the ORR, OS and 1-year survival rate were 16.0-55.0%, 9.0-13.9 months and 44.0-58.0%, respectively (15,(18)(19)(20). The incidence of adverse events, such as grade 3/4 neutropenia (80.0%) and febrile neutropenia (8.0%), was similar to those previously reported (51.1-79.0 and 3.3-26.0%, respectively).…”

Section: Discussionmentioning

confidence: 98%

“…Taxanes are able to drive COX-2 expression, which is followed by increased prostaglandin E 2 (PGE 2 ) production (14); therefore, a complementary and additive or synergistic effect with COX-2 inhibitors may be expected. Moreover, the response to carboplatin plus docetaxel in Asian patients was reported to be statistically superior to that in Caucasian patients (15).…”

Section: Introductionmentioning

confidence: 98%

Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review

Yokouchi

Kanazawa

Ishida

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Several preclinical and clinical studies have demonstrated that cyclooxygenase-2 (COX-2) inhibitors are efficient for the treatment of non-small-cell lung cancer (NSCLC). However, two recent phase III clinical trials using COX-2 inhibitors in combination with platinum-based chemotherapy failed to demonstrate a survival benefit. Thus, validation and discussion regarding the usefulness of COX-2 inhibitors for patients with NSCLC are required. We conducted a prospective trial using COX-2 inhibitors for the treatment of 50 NSCLC patients accrued between April, 2005 and July, 2006. Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg̸ml x min on day 1) and docetaxel (60 mg/m 2 on day 1) every 3 weeks. The primary endpoint was response rate. The response and disease control rates were 36.0 and 76.0%, respectively. The time-to-progression (TTP) and overall survival (OS) were 5.7 months [95% confidence interval (CI): 4.6-6.7] and 13.7 months (95% CI: 11.4-15.9), respectively. The 1-year survival ratio was 56.0%. Grade 3 neuropathy was observed in only 1 patient. We performed tumor immunohistochemistry for COX-2 and p27 and investigated the correlation between their expression and clinical outcome. COX-2 expression in the tumor tended to correlate with a higher response rate (50.0% in the high-and 18.2% in the low-COX-2 group; P=0.092). Based on our results and previous reports, various trial designs, such as the prospective use of COX-2 inhibitors only for patients with COX-2-positive NSCLC, including the exploratory analysis of biomarkers associated with the COX-2 pathway, may be worth further consideration. IntroductionCyclooxygenase-2 (COX-2), the enzyme that converts arachidonic acid to prostaglandins (PGs), is expressed in a number of solid tumors and is associated with carcinogenesis, tumor proliferation, infiltration, metastasis, angiogenesis and resistance to anticancer drugs (1). In lung cancer cells, COX-2, which is particularly overexpressed in adenocarcinoma (2), is considered to be a negative predictor of survival in this subpopulation (3-7). Based on these reports, several clinical trials have been conducted for the potentiation of targeting COX-2 in lung cancer (8).The cyclin-dependent kinase (Cdk) inhibitor p27 plays a critical role in cell cycle regulation from the G1 to the S phase by inhibiting Cdk4/6-cyclin D1 and Cdk2-cyclin E (9). Loss of p27 expression tends to be an unfavorable prognostic factor in patients with non-small-cell lung cancer (NSCLC) (10). Increased p27 expression is attributed to COX-2-independent mechanisms of G0/G1 arrest driven by COX-2 inhibitors (11). Thus, p27 expression may be another predictive factor of the response to COX-2 inhibitors.Taxanes, such as paclitaxel and docetaxel, are microtubule-stabilizing agents that act by interfering with spindle microtubule dynamics, causing cell cycle arrest and apoptosis through activating a number of molecular pathways (12,13). Taxanes are able to drive COX-2...

show abstract

Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients

Abstract: This regimen is active in advanced NSCLC. The potential impact of ethnicity on efficacy and toxicity of treatment requires further investigation.

Cited by 93 publications

References 19 publications

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC

Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review

Contact Info

Product

Resources

About